Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin tests

European Annals of Allergy and Clinical Immunology

Volumn 45, Issue 5, 2013, Pages 181-182

  Cortellini, Gabriele ^a   Amadori, A ^b   Comandini, T ^b   Corvetta, A ^a  

^a Internal Medicine and Rheumatology Rimini Hospital   (Italy)

^b Neurology Department Rimini Hospital   (Italy)

Author keywords

Beta 1a Interferon; Multiple sclerosis (MS); Non irritating concentration (NIC)

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BETA1A INTERFERON; CORTICOSTEROID; GLATIRAMER; IMMUNOGLOBULIN E; BETA INTERFERON;

ADULT; ALLERGIC URTICARIA; ALLERGY TEST; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; DYSPNEA; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; MAINTENANCE THERAPY; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NON IRRITATING CONCENTRATION; PRICK TEST; RASH; SKIN PRURITUS; SKIN TEST; STANDARDIZATION; TREATMENT RESPONSE; ANAPHYLAXIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; METHODOLOGY; CHEMICALLY INDUCED; PROCEDURES;

ADULT; ANAPHYLAXIS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INTERFERON-BETA; SKIN TESTS;

EID: 84892151315     PISSN: 17641489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Munschauer FE 3rd, Kinkel RP: Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997; 19: 883-93.
2. Mazzeo L, Ricciardi L, Fazio MC, Fogliani O, Fedele R, Ferlazzo E, Isola S: Severe urticaria due to recombinant interferon beta-1a. Br JDermatol 2003; 148: 171-92.
3. Guijarro C, Benito-Leòn J, Bermejo-Pareja F: Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis Neurol Sci. Apr; 32(2): 309-11.
4. Corona T, Leon C, Ostrosky-Zeicher L: Severe anaphylaxis with recombinant interferon beta. Neurology 1999; 52: 425.
5. García-F-Villalta M, Daudén E, Sánchez J, Fraga J, Ramo C, García-Díez A: Local reactions associated with subcutaneous injections of both beta-interferon 1a and 1b. Acta Derm Venereol 2001; 81: 152.
6. Fusun Kalpaklioglu A, Baccioglu Kavut A, Erdemoglu AK: Desensitization in interferon-beta1a allergy: a case report. Int Arch Allergy Immunol. 2009; 149(2): 178-80.
7. Brown DL, Login IS, Borish L, Powers PL: An urticarial IgE mediated reaction to interferon beta-1b. Neurology 2001; 56: 1416-7.
8. Ohmoto K, Yamamoto S: Angioedema after interferon therapy for chronic hepatitis C. Am J Gastroenterol 2001; 96: 1311-12.
9. Noronha A, Toscas A, Jensen MA: Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145-53.
10. Pichler WJ, Campi P: Adverse side effects to biological agents; in Pichler WJ (ed): Drug Hypersensitivity. Basel, Karger, 2007, pp 151-65.
11. Cohen BA, Greenberger PA, Saini S: Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b. Allergy Asthma Proc 1998; 19: 85-8.